Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

• Phase: Phase 4

Details

• Lead Sponsor: Innovative Medical
• Treatments: Bimatoprost; Timolol; Travoprost

Criteria

Inclusion Criteria:

• · Male or female > 18 years of age

• Diagnosis of primary open-angle glaucoma or ocular hypertension

• Untreated IOP > 18 mm Hg in each eye at the baseline evaluation

• Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

• · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication

• Uncontrolled systemic disease

• Active ocular disease other than POAG or ocular hypertension

• Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted)

• History of intraocular surgery within the last 3 months

• Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance